Altogether, these data indicate that POLE‐mutated CRC had an immune profile closer to MMR‐D than MMR‐P tumors, suggesting they could exert an antitumor activity in POLE‐mutated CRC so as in MMR‐D CRC, independently of PD‐L1 expression. This evidence concerns the gene POLE and colorectal carcinoma.